US FDA accepts for priority review GSK’s NDA for gepotidacin to treat uncomplicated urinary tract infections in female adults and adolescents: London, UK Thursday, October 17, 2 ...
GSK announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for gepotidacin, a first-in-class oral antibiotic, under priority review.
(Alliance News) - GSK PLC on Wednesday announced that the US Food & Drug Administration has accepted its New Drug Application for gepotidacin. The London-based biopharma company said the FDA has ...
Here is what you need to know at the London market open: FTSE 100: opened up 56.75 points, or 0.7%, at 8,306.03 Hang Seng: up 0.3% at 20,371.80 Nikkei 225: closed down 1.8% at 39,180.30 S&P/ASX 200: ...